ImmunityBio, Inc.ImmunityBio, Inc.ImmunityBio, Inc.

ImmunityBio, Inc.

No trades
See on Supercharts
Market capitalization
‪3.44 B‬USD
−1.13USD
‪−583.20 M‬USD
‪622.00 K‬USD
‪136.93 M‬
Beta (1Y)
1.23

About ImmunityBio, Inc.

CEO
Richard Adcock
Headquarters
San Diego
Employees (FY)
628
Founded
2014
ISIN
US45256X1037
FIGI
BBG007T9DYW9
ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of IBRX is 5.24 USD — it has increased by 2.54% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ImmunityBio, Inc. stocks are traded under the ticker IBRX.
ImmunityBio, Inc. is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for ImmunityBio, Inc. has a max estimate of 5.00 USD and a min estimate of 5.00 USD.
IBRX earnings for the last quarter are −0.19 USD whereas the estimation was −0.26 USD which accounts for 25.49% surprise. Estimated earnings for the next quarter are −0.18 USD. See more details about ImmunityBio, Inc. earnings.
ImmunityBio, Inc. revenue for the last quarter amounts to ‪82.00 K‬ USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach ‪25.00 K‬ USD.
Yes, you can track ImmunityBio, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, IBRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ImmunityBio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
IBRX reached its all-time high on Feb 22, 2021 with the price of 45.42 USD, and its all-time low was 0.93 USD and was reached on Dec 26, 2018.
See other stocks reaching their highest and lowest prices.
As of Apr 16, 2024, the company has 628.00 employees. See our rating of the largest employees — is ImmunityBio, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ImmunityBio, Inc. EBITDA is ‪−339.62 M‬ USD, and current EBITDA margin is ‪−55.12 K‬%. See more stats in ImmunityBio, Inc. financial statements.